Cancer firm AVO buys Large Hadron Collider spin-off

Google+ Pinterest LinkedIn Tumblr +

A BRITISH CANCER treatment company is buying a business spun off from technology developed from the Large Hadron Collider which was designed to recreate the conditions of the Big Bang.

Aim-listed Advanced Oncotherapy (AVO) has signed an all-share deal to acquire Adam SA, founded by experts working at CERN on the Swiss-French border.

Current cancer treatment fires X-rays and electron beams at the body to kill cancer cells, but these can cause harm to surrounding tissue. AVO hopes that by purchasing Adam it can use the company’s expertise to provide more focused treatment to minimise the side-effects.

AVO currently offers proton radiotherapy which can be used more accurately to target tumours, reducing damage to nearby organs.

Adam focuses on designing and building particle accelerators that are much smaller than the 250ft rings currently needed at international nuclear research project near Geneva. It is currently working on a compact linear accelerator which is capable of firing protons and whose small size means it can more easily be installed in hospitals.

Proton beam therapy is currently available in just 32 hospitals around the world and just one in the UK – the Clatterbridge Cancer Centre, where it is used to treat eye tumours. Two more proton beam therapy centres are planned in Britain – with one due to be built in Manchester and another in London…read full article

Source: Telegraph.co.uk

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.